Sex differences in the pharmacokinetics of antidepressants: Influence of female sex hormones and oral contraceptives

Clinical Pharmacokinetics

Volumn 53, Issue 6, 2014, Pages 509-519

  Damoiseaux, Valérie A ^a   Proost, Johannes H ^a   Jiawan, Vincent C R ^b   Melgert, Barbro N ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; ESTRADIOL; ESTROGEN; FOLLITROPIN; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; SEX HORMONE;

BLOOD BRAIN BARRIER; CLINICAL TRIAL (TOPIC); DEPRESSION; DEVELOPMENTAL STAGE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG PROTEIN BINDING; FEMALE; FLUID RETENTION; FOLLICULAR PHASE; HORMONE SUBSTITUTION; HUMAN; INTESTINE TRANSIT TIME; LUTEAL PHASE; MALE; MENOPAUSE; MENSTRUAL CYCLE; ORAL CONTRACEPTIVE USE; POSTMENOPAUSE; PREGNANCY; PRIORITY JOURNAL; PSYCHOEDUCATION; PSYCHOTHERAPY; PUBERTY; REVIEW; SEX DIFFERENCE; TREATMENT RESPONSE; WATER SUPPLY; ANIMAL; METABOLISM; ONSET AGE;

AGE OF ONSET; ANIMALS; ANTIDEPRESSIVE AGENTS; CONTRACEPTIVES, ORAL; DEPRESSION; FEMALE; GONADAL STEROID HORMONES; HUMANS; MALE; SEX FACTORS;

EID: 84903692659     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-014-0145-2     Document Type: Review

References (105)

1. WHO depression fact sheet. http://www.who.int/mediacentre/factsheets/ fs369/en/index.html. Accessed 23 May 2013
2. Association AP. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
3. Dimock K, McGrath S, Cook L. The nervous system: antidepressant drugs. In: Rang HP, Dale MM, Ritter JM, Flower RJ, editors. Rang and Dale's pharmacology. 6th ed. Oxford: Elsevier, Ltd; 2007. pp. 557-73.
4. Fernandez-Guasti A, Fiedler JL, Herrera L, Handa RJ. Sex, stress, and mood disorders: at the intersection of adrenal and gonadal hormones. Horm Metab Res. 2012;44:607-18.
5. Brigitta B. Pathophysiology of depression and mechanisms of treatment. Dialogues Clin Neurosci. 2002;4:7-20.
6. Angst J, Gamma A, Gastpar M, Lepine JP, Mendlewicz J, Tylee A, et al. Gender differences in depression. Epidemiological findings from the European DEPRES I and II studies. Eur Arch Psychiatry Clin Neurosci. 2002;252:201-9. (Pubitemid 36068381)
7. Frackiewicz EJ, Sramek JJ, Cutler NR. Gender differences in depression and antidepressant pharmacokinetics and adverse events. Ann Pharmacother. 2000;34:80-8. (Pubitemid 30058927)
8. Grigoriadis S, Robinson GE. Gender issues in depression. Ann Clin Psychiatry. 2007;19:247-55. (Pubitemid 350208795)
9. Pae CU, Mandelli L, Kim TS, Han C, Masand PS, Marks DM, et al. Effectiveness of antidepressant treatments in pre-menopausal versus post-menopausal women: a pilot study on differential effects of sex hormones on antidepressant effects. Biomed Pharmacother. 2009;63:228-35.
10. Freeman EW, Sammel MD, Liu L, Gracia CR, Nelson DB, Hollander L. Hormones and menopausal status as predictors of depression in women in transition to menopause. Arch Gen Psychiatry. 2004;61:62-70. (Pubitemid 38044642)
11. Freeman EW. Associations of depression with the transition to menopause. Menopause. 2010;17:823-7.
12. Kendler KS, Karkowski LM, Prescott CA. Causal relationship between stressful life events and the onset of major depression. Am J Psychiatry. 1999;156:837-41. (Pubitemid 29260336)
13. Keers R, Aitchison KJ. Gender differences in antidepressant drug response. Int Rev Psychiatry. 2010;22:485-500.
14. Ormel J, Jeronimus BF, Kotov R, Riese H, Bos EH, Hankin B, et al. Neuroticism and common mental disorders: meaning and utility of a complex relationship. Clin Psychol Rev. 2013;33:686-97.
15. Kendler KS, Gardner CO. Sex differences in the pathways to major depression: a study of opposite-sex twin pairs. Am J Psychiatry. 2014;171:426-35.
16. Khan A, Brodhead AE, Schwartz KA, Kolts RL, Brown WA. Sex differences in antidepressant response in recent antidepressant clinical trials. J Clin Psychopharmacol. 2005;25:318-24. (Pubitemid 41060250)
17. Young EA, Kornstein SG, Marcus SM, Harvey AT, Warden D, Wisniewski SR, et al. Sex differences in response to citalopram: a STAR*D report. J Psychiatr Res. 2009;43:503-11.
18. Baca E, Garcia-Garcia M, Porras-Chavarino A. Gender differences in treatment response to sertraline versus imipramine in patients with nonmelancholic depressive disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:57-65. (Pubitemid 37548498)
19. Pomara N, Shao B, Choi SJ, Tun H, Suckow RF. Sex-related differences in nortriptyline-induced side-effects among depressed patients. Prog Neuropsychopharmacol Biol Psychiatry. 2001;25:1035-48. (Pubitemid 32769996)
20. Kornstein SG, Schatzberg AF, Thase ME, Yonkers KA, McCullough JP, Keitner GI, et al. Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry. 2000;157:1445-52.
21. Joyce PR, Mulder RT, Luty SE, Sullivan PF, McKenzie JM, Abbott RM, et al. Patterns and predictors of remission, response and recovery in major depression treated with fluoxetine or nortriptyline. Aust N Z J Psychiatry. 2002;36:384-91. (Pubitemid 34777988)
22. Naito S, Sato K, Yoshida K, Higuchi H, Takahashi H, Kamata M, et al. Gender differences in the clinical effects of fluvoxamine and milnacipran in Japanese major depressive patients. Psychiatry Clin Neurosci. 2007;61:421-7. (Pubitemid 47019913)
23. Berlanga C, Flores-Ramos M. Different gender response to serotonergic and noradrenergic antidepressants. A comparative study of the efficacy of citalopram and reboxetine. J Affect Disord. 2006;95:119-23. (Pubitemid 46107028)
24. Thase ME, Entsuah R, Cantillon M, Kornstein SG. Relative antidepressant efficacy of venlafaxine and SSRIs: sex-age interactions. J Womens Health (Larchmt). 2005;14:609-16. (Pubitemid 41488679)
25. Martenyi F, Dossenbach M, Mraz K, Metcalfe S. Gender differences in the efficacy of fluoxetine and maprotiline in depressed patients: a double-blind trial of antidepressants with serotonergic or norepinephrinergic reuptake inhibition profile. Eur Neuropsychopharmacol. 2001;11:227-32. (Pubitemid 32618645)
26. Papakostas GI, Kornstein SG, Clayton AH, Soares CN, Hallett LA, Krishen A, et al. Relative antidepressant efficacy of bupropion and the selective serotonin reuptake inhibitors in major depressive disorder: gender-age interactions. Int Clin Psychopharmacol. 2007;22:226-9. (Pubitemid 46801946)
27. Wohlfarth T, Storosum JG, Elferink AJA, van Zwieten BJ, Fouwels A, van den Brink W. Response to tricyclic antidepressants: independent of gender? Am J Psychiatry. 2004;161:370-2. (Pubitemid 38419292)
28. Parker G, Parker K, Austin MP, Mitchell P, Brotchie H. Gender differences in response to differing antidepressant drug classes: two negative studies. Psychol Med. 1999;33:1473-7. (Pubitemid 37483470)
29. Hildebrandt MG, Steyerberg EW, Stage KB, Passchier J, Kragh-Soerensen P. Danish University Antidepressant Group. Are gender differences important for the clinical effects of antidepressants? Am J Psychiatry. 2003;160:1643-50. (Pubitemid 41079551)
30. Quitkin FM, Stewart JW, McGrath PJ, Taylor BP, Tisminetzky MS, Petkova E, et al. Are there differences between women's and men's antidepressant responses? Am J Psychiatry. 2002;159:1848-54. (Pubitemid 35283249)
31. Kornstein SG. Gender differences in depression: implications for treatment. J Clin Psychiatry. 1997;58(Suppl 15):12-8. (Pubitemid 28047250)
32. Sloan DM, Kornstein SG. Gender differences in depression and response to antidepressant treatment. Psychiatr Clin N Am. 2003;26:581-94. (Pubitemid 37175497)
33. Marcus SM, Young EA, Kerber KB, Kornstein S, Farabaugh AH, Mitchell J, et al. Gender differences in depression: findings from the STAR*D study. J Affect Disord. 2005;87:141-50. (Pubitemid 41039936)
34. Kokras N, Dalla C, Papadopoulou-Daifoti Z. Sex differences in pharmacokinetics of antidepressants. Expert Opin Drug Metab Toxicol. 2011;7:213-26.
35. Gex-Fabry M, Balant-Gorgia AE, Balant LP, Garrone G. Clomipramine metabolism. Model-based analysis of variability factors from drug monitoring data. Clin Pharmacokinet. 1990;19:241-55. (Pubitemid 20281453)
36. Ronfeld RA, Tremaine LM, Wilner KD. Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers. Clin Pharmacokinet. 1997;32(Suppl 1):22-30. (Pubitemid 27107716)
37. Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet. 1997;32(Suppl 1):1-21. (Pubitemid 27107715)
38. Morishita S, Kinoshita T. Predictors of response to sertraline in patients with major depression. Hum Psychopharmacol. 2008;23:647-51.
39. Soldin OP, Mattison DR. Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2009;48:143-57.
40. Kashuba AD, Nafziger AN. Physiological changes during the menstrual cycle and their effects on the pharmacokinetics and pharmacodynamics of drugs. Clin Pharmacokinet. 1998;34:203-18. (Pubitemid 28112399)
41. Berg MJ. Gender-specific prescribing: medications and the menstrual cycle. J Gend Specif Med. 1998;1:17-9.
42. Haus E, Nicolau GY, Lakatua DJ, Sackett-Lundeen L, Petrescu E, Swoyer J. Chronobiology in laboratory medicine. Ann Ist Super Sanita. 1993;29:581-606.
43. Grossman MI, Kirsner JB, Gillespie IE. Basal and histalog-stimulated gastric secretion in control subjects and in patients with peptic ulcer or gastric cancer. Gastroenterology. 1963;45:14-26.
44. Wald A, Van Thiel DH, Hoechstetter L, Gavaler JS, Egler KM, Verm R, et al. Gastrointestinal transit: the effect of the menstrual cycle. Gastroenterology. 1981;80:1497-500. (Pubitemid 11113567)
45. Horowitz M, Maddern GJ, Chatterton BE, Collins PJ, Petrucco OM, Seamark R, et al. The normal menstrual cycle has no effect on gastric emptying. Br J Obstet Gynaecol. 1985;92:743-6. (Pubitemid 15048757)
46. Jones BM, Jones MK. Alcohol effects in women during the menstrual cycle. Ann N Y Acad Sci. 1976;273:576-87.
47. Mones J, Carrio I, Calabuig R, Estorch M, Sainz S, Berna L, et al. Influence of the menstrual cycle and of menopause on the gastric emptying rate of solids in female volunteers. Eur J Nucl Med. 1993;20:600-2. (Pubitemid 23256130)
48. Hsu JJ, Kim CH, O'Connor MK, Brown ML. Effect of menstrual cycle on esophageal emptying of liquid and solid boluses. Mayo Clin Proc. 1993;68:753-6. (Pubitemid 23222299)
49. Yonkers KA, Kando JC, Cole JO, Blumenthal S. Gender differences in pharmacokinetics and pharmacodynamics of psychotropic medication. Am J Psychiatry. 1992;149:587-95.
50. Nicolas JM, Espie P, Molimard M. Gender and interindividual variability in pharmacokinetics. Drug Metab Rev. 2009;41:408-21.
51. Bisdee JT, Garlick PJ, James WP. Metabolic changes during the menstrual cycle. Br J Nutr. 1989;61:641-50. (Pubitemid 19180389)
52. Gleichauf CN, Roe DA. The menstrual cycle's effect on the reliability of bioimpedance measurements for assessing body composition. Am J Clin Nutr. 1989;50:903-7. (Pubitemid 19280011)
53. Fruzzetti F, Lello S, Lazzarini V, Fratta S, Orru M, Sorge R, et al. The oral contraceptive containing 30 microg of ethinylestradiol plus 3 mg of drospirenone is able to antagonize the increase of extracellular water occurring in healthy young women during the luteal phase of the menstrual cycle: an observational study. Contraception. 2007;75:199-203. (Pubitemid 46217183)
54. Jochemsen R, van der Graaff M, Boeijinga JK, Breimer DD. Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. Br J Clin Pharmacol. 1982;13:319-24. (Pubitemid 13138228)
55. Shavit G, Lerman P, Korczyn AD, Kivity S, Bechar M, Gitter S. Phenytoin pharmacokinetics in catamenial epilepsy. Neurology. 1984;34:959-61. (Pubitemid 14076466)
56. Cederblad G, Hahn L, Korsan-Bengtsen K, Pehrsson NG, Rybo G. Variations in blood coagulation, fibrinolysis, platelet function and various plasma proteins during the menstrual cycle. Haemostasis. 1977;6:294-302. (Pubitemid 8234510)
57. Benet LZ, Hoener BA. Changes in plasma protein binding have little clinical relevance. Clin Pharmacokinet Ther. 2002;71:115-21. (Pubitemid 34271114)
58. Schmidt S, Gonzalez D, Derendorf H. Significance of protein binding in pharmacokinetics and pharmacodynamics. J Pharm Sci. 2010;99:1107-22.
59. Bigos KL, Pollock BG, Stankevich BA, Bies RR. Sex differences in the pharmacokinetics and pharmacodynamics of antidepressants: an updated review. Gend Med. 2009;6:522-43.
60. Abernethy DR, Greenblatt DJ, Shader RI. Imipramine disposition in users of oral contraceptive steroids. Clin Pharmacol Ther. 1984;35:792-7. (Pubitemid 14077485)
61. Higashi E, Fukami T, Itoh M, Kyo S, Inoue M, Yokoi T, et al. Human CYP2A6 is induced by estrogen via estrogen receptor. Drug Metab Dispos. 2007;35:1935-41. (Pubitemid 47481589)
62. Dickmann LJ, Isoherranen N. Quantitative prediction of CYP2B6 induction by estradiol during pregnancy: potential explanation for increased methadone clearance during pregnancy. Drug Metab Dispos. 2013;41:270-4.
63. Palovaara S, Pelkonen O, Uusitalo J, Lundgren S, Laine K. Inhibition of cytochrome P450 2B6 activity by hormone replacement therapy and oral contraceptive as measured by bupropion hydroxylation. Clin Pharmacol Ther. 2003;74:326-33. (Pubitemid 37222853)
64. Thompson DS, Kirshner MA, Klug TL, Kastango KB, Pollock BG. A preliminary study of the effect of fluoxetine treatment on the 2:16-alpha-hydroxyestrone ratio in young women. Ther Drug Monit. 2003;25:125-8. (Pubitemid 36139839)
65. Soldin OP, Chung SH, Mattison DR. Sex differences in drug disposition. J Biomed Biotechnol. 2011;2011:187103.
66. DelRosario GA, Chang AC, Lee ED. Postpartum depression: symptoms, diagnosis, and treatment approaches. JAAPA. 2013;26:50-4.
67. Parker G, Brotchie H. Gender differences in depression. Int Rev Psychiatry. 2010;22:429-36.
68. Hazell P, Mirzaie M. Tricyclic drugs for depression in children and adolescents. Cochrane Database Syst Rev. 2013;6:CD002317.
69. Steer RA, Scholl TO, Hediger ML, Fischer RL. Self-reported depression and negative pregnancy outcomes. J Clin Epidemiol. 1992;45:1093-9.
70. Deligiannidis KM, Byatt N, Freeman MP. Pharmacotherapy for mood disorders in pregnancy: a review of pharmacokinetic changes and clinical recommendations for therapeutic drug monitoring. J Clin Psychopharmacol. 2014;34:244-55.
71. Aldridge A, Bailey J, Neims AH. The disposition of caffeine during and after pregnancy. Semin Perinatol. 1981;5:310-4.
72. Wisner KL, Perel JM, Wheeler SB. Tricyclic dose requirements across pregnancy. Am J Psychiatry. 1993;150:1541-2. (Pubitemid 23289315)
73. Abernethy DR, Todd EL. Impairment of caffeine clearance by chronic use of low-dose oestrogen-containing oral contraceptives. Eur J Clin Pharmacol. 1985;28:425-8. (Pubitemid 15063812)
74. Baylis F. Pregnant women deserve better. Nature. 2010;465:689-90.
75. Utian WH. The International Menopause Society menopause-related terminology definitions. Climacteric. 1999;2:284-6. (Pubitemid 30084457)
76. Cohen LS. Gender-specific considerations in the treatment of mood disorders in women across the life cycle. J Clin Psychiatry. 2003;64(Suppl 15):18-29. (Pubitemid 37464493)
77. Oesterheld JR, Cozza K, Sandson NB. Oral contraceptives. Psychosomatics. 2008;49:168-75. (Pubitemid 351364992)
78. Zhang H, Cui D, Wang B, Han YH, Balimane P, Yang Z, et al. Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug. Clin Pharmacokinet. 2007;46:133-57. (Pubitemid 46193058)
79. Benowitz NL, Lessov-Schlaggar CN, Swan GE, Jacob P 3rd. Female sex and oral contraceptive use accelerate nicotine metabolism. Clin Pharmacol Ther. 2006;79:480-8.
80. Miners JO, Robson RA, Birkett DJ. Gender and oral contraceptive steroids as determinants of drug glucuronidation: effects on clofibric acid elimination. Br J Clin Pharmacol. 1984;18:240-3. (Pubitemid 14054878)
81. Walle T, Fagan TC, Walle UK, Topmiller MJ. Stimulatory as well as inhibitory effects of ethinyloestradiol on the metabolic clearances of propranolol in young women. Br J Clin Pharmacol. 1996;41:305-9. (Pubitemid 26114818)
82. Monig H, Baese C, Heidemann HT, Ohnhaus EE, Schulte HM. Effect of oral contraceptive steroids on the pharmacokinetics of phenprocoumon. Br J Clin Pharmacol. 1990;30:115-8. (Pubitemid 20225462)
83. Herman RJ, Loewen GR, Antosh DM, Taillon MR, Hussein S, Verbeeck RK. Analysis of polymorphic variation in drug metabolism: III. Glucuronidation and sulfation of diflunisal in man. Clin Invest Med. 1994;17:297-307. (Pubitemid 24308626)
84. Sabers A, Buchholt JM, Uldall P, Hansen EL. Lamotrigine plasma levels reduced by oral contraceptives. Epilepsy Res. 2001;47:151-4. (Pubitemid 32973655)
85. Gu L, Gonzalez FJ, Kalow W, Tang BK. Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. Pharmacogenetics. 1992;2:73-7.
86. Roberts RK, Grice J, McGuffie C, Heilbronn L. Oral contraceptive steroids impair the elimination of theophylline. J Lab Clin Med. 1983;101:821-5. (Pubitemid 13100676)
87. Zhang ZY, Kaminsky LS. Characterization of human cytochromes P450 involved in theophylline 8-hydroxylation. Biochem Pharmacol. 1995;50:205-11.
88. Somani SM, Khurana RC. Mechanism of estrogen-imipramine interaction. JAMA. 1973;223:560.
89. Koke SC, Brown EB, Miner CM. Safety and efficacy of fluoxetine in patients who receive oral contraceptive therapy. Am J Obstet Gynecol. 2002;187:551-5.
90. Luscombe DK, John V. Influence of age, cigarette smoking and the oral contraceptive on plasma concentrations of clomipramine. Postgrad Med J. 1980;56(Suppl 1):99-102. (Pubitemid 10119394)
91. Brachtendorf L, Jetter A, Beckurts KT, Holscher AH, Fuhr U. Cytochrome P450 enzymes contributing to demethylation of maprotiline in man. Pharmacol Toxicol. 2002;90:144-9. (Pubitemid 34289612)
92. Paaby P, Moller-Petersen J, Larsen CE, Raffn K. Endogenous overnight creatinine clearance, serum beta 2-microglobulin and serum water during the menstrual cycle. Acta Med Scand. 1987;221:191-7. (Pubitemid 17072879)
93. Christy NP, Shaver JC. Estrogens and the kidney. Kidney Int. 1974;6:366-76.
94. Harvey AM, Malvin RL, Vander AJ. Comparison of creatinine secretion in men and women. Nephron. 1966;3:201-5.
95. Nafziger AN, Schwartzman MS, Bertino JS Jr. Absence of tobramycin pharmacokinetic and creatinine clearance variation during the menstrual cycle: implied absence of variation in glomerular filtration rate. J Clin Pharmacol. 1989;29:757-63. (Pubitemid 19222381)
96. Davison JM, Noble MC. Serial changes in 24 hour creatinine clearance during normal menstrual cycles and the first trimester of pregnancy. Br J Obstet Gynaecol. 1981;88:10-7. (Pubitemid 11184003)
97. Forsling ML, Akerlund M, Stromberg P. Variations in plasma concentrations of vasopressin during the menstrual cycle. J Endocrinol. 1981;89:263-6. (Pubitemid 11111523)
98. Katz FH, Romfh P. Plasma aldosterone and renin activity during the menstrual cycle. J Clin Endocrinol Metab. 1972;34:819-21.
99. Olson BR, Forman MR, Lanza E, McAdam PA, Beecher G, Kimzey LM, et al. Relation between sodium balance and menstrual cycle symptoms in normal women. Ann Intern Med. 1996;125:564-7. (Pubitemid 126450089)
100. Albano JD, Campbell SK, Farrer A, Millar JG. Gender differences in urinary kallikrein excretion in man: variation throughout the menstrual cycle. Clin Sci. 1994;86:227-31. (Pubitemid 24056704)
101. Brennan IM, Feltrin KL, Nair NS, Hausken T, Little TJ, Gentilcore D, et al. Effects of the phases of the menstrual cycle on gastric emptying, glycemia, plasma GLP-1 and insulin, and energy intake in healthy lean women. Am J Physiol Gastrointest Liver Physiol. 2009;297:G602-10.
102. Miller SB, Sita A. Parental history of hypertension, menstrual cycle phase, and cardiovascular response to stress. Psychosom Med. 1994;56:61-9. (Pubitemid 24054874)
103. Dunne FP, Barry DG, Ferriss JB, Grealy G, Murphy D. Changes in blood pressure during the normal menstrual cycle. Cli Sci (Lond). 1991;81:515-8.
104. Tersman Z, Collins A, Eneroth P. Cardiovascular responses to psychological and physiological stressors during the menstrual cycle. Psychosom Med. 1991;53:185-97.
105. Webb P. 24-hour energy expenditure and the menstrual cycle. Am J Clin Nutr. 1986;44:614-9. (Pubitemid 17194664)